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The canine infectious respiratory disease complex (CIRDC) is an endemicworldwide syndrome involvingmultiple
viral andbacterialpathogens.Traditionally,Bordetella bronchiseptica (Bb), canineadenovirus type2 (CAV-2), canine
distempervirus (CDV), canineherpesvirus (CHV)andcanineparainfluenzavirus (CPiV)wereconsidered thema-
jor causative agents. Lately, new pathogens have been implicated in the development of CIRDC, namely canine
influenza virus (CIV), canine respiratory coronavirus (CRCoV), canine pneumovirus (CnPnV),Mycoplasma cynos
and Streptococcus equi subspecies zooepidemicus. To better understand the role of the different pathogens in the devel-
opment of CIRDC and their epidemiological relevance in Europe, prevalence data were collected from peer-
reviewed publications and summarized. Evidence of exposure to Bb is frequently found in healthy and diseased
dogs and client-owned dogs are as likely to be infected as kennelled dogs. Co-infections with viral pathogens are
common. The findings confirm that Bb is an important cause of CIRDC in Europe. CAV-2 and CDV recovery
rates fromhealthy and diseased dogs are low and themost likely explanation for this is control through vaccination.
Seroconversion toCHVcanbedemonstrated followingCIRDCoutbreaks andCHVhasbeendetected in the lower
respiratory tract of diseased dogs. There is some evidence that CHV is not a primary cause of CIRDC, but oppor-
tunistically re-activates at the time of infection and exacerbates the disease. The currently available data suggest
thatCIV is, at present, neither a prevalent nor a significant pathogen inEurope.CPiV remains an important path-
ogen in CIRDC and facilitates co-infection with other viral and bacterial pathogens. CnPnV and CRCoV are
important new elements in the aetiology of CIRDC and spread particularly well in multi-dog establishments.
M. cynos is common inEurope and ismore likely to occur in younger andkennelleddogs.This organism is frequently
found together with other CIRDC pathogens and is significantly associated with more severe respiratory signs. S.
zooepidemicus infection is not common and appears to be a particular problem in kennels. Protective immunity
against respiratory diseases is rarely complete, and generally only a reduction in clinical signs and excretion of path-
ogen can be achieved through vaccination. However, even vaccines that only reduce and do not prevent infection
carry epidemiological advantages. They reduce spread, increase herd immunity and decrease usage of antimicro-
bials. Recommending vaccination of dogs against pathogens of CIRDC will directly provide epidemiological ad-
vantages to the population and the individual dog.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: canine infectious respiratory disease complex; dog; pathogen; vaccinationondence to: M. J. Day (e-mail: profmjday@gmail.com).
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The canine infectious respiratory disease complex
(CIRDC) is an endemic worldwide syndrome
involving multiple viral and bacterial pathogens
(LeRoith et al., 2012). Host and environmental fac-
tors play a role in the development of the disease
and its severity. CIRDC has been referred to histor-
ically as ‘kennel cough’ or ‘canine infectious
tracheobronchitis’ and is described as an acute,
highly contagious respiratory infection of dogs.
The disease is characterized by sudden onset,
paroxysmal, dry, ‘honking’ cough with variable
expectoration and naso-ocular discharge (Ford
and Vaden, 1998). Signs last for days to weeks
and are mild to moderate in most dogs. In puppies
and dogs with immunosuppression or other concur-
rent diseases, CIRDC can be complicated by bron-
chopneumonia, resulting in more severe signs such
as dyspnoea, weight loss, pyrexia and even death
(Radhakrishnan et al., 2007).
CIRDC can affect dogs of all ages and causes spo-
radic illness as well as outbreaks (Dear, 2014). It
commonly spreads where large numbers of dogs are
housed in close confinement (e. g. in shelters or board-
ing kennels) or are gathered (e. g. at dog shows and
training classes) (Erles et al., 2004). The disease is
rapidly transmitted through droplets or asymptom-atic carriers as most of its pathogens are ubiquitous.
It is thought that, in most cases, viral infections
initially damage the epithelium of the upper respira-
tory tract (Ford and Vaden, 1998), allowing second-
ary bacterial infections to add to the destruction and
inflammation in the upper respiratory tract. As the
host immune response is initiated, spread of the infec-
tion into the lower respiratory tract is normally pre-
vented and the infection eventually cleared. Under
adverse circumstances however, the infection may
reach the lower airways and cause pneumonia or
chronic respiratory disease.
Many bacteria and viruses can be involved in
CIRDC. Traditionally, Bordetella bronchiseptica (Bb),
canine adenovirus type 2 (CAV-2), canine distemper
virus (CDV), canine herpesvirus (CHV) and canine
parainfluenza virus (CPiV) were considered the ma-
jor causative agents. Lately, new pathogens have
been implicated in the development of CIRDC,
namely canine influenza virus (CIV), canine respira-
tory coronavirus (CRCoV), canine pneumovirus
(CnPnV), Mycoplasma cynos and Streptococcus equi sub-
species zooepidemicus (S. zooepidemicus). Finally, canine
bocavirus and canine hepacivirus have been isolated
and/or loosely associated with respiratory disease in
dogs (Priestnall et al., 2014), but are not considered
further in this review.
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Bb is a gram-negative, aerobic coccobacillus (re-
viewed by Goodnow, 1980). Many mammals are sus-
ceptible to infection with Bb including dogs. Research
has concentrated on Bb infections in pigs (atrophic
rhinitis), dogs (CIRDC), laboratory animals (bron-
chopneumonia) and increasingly man (Woolfrey
and Moody, 1991; Ducours et al., 2017). The
bacterium can act as a primary pathogen in dogs
(Wright et al., 1973) or cause CIRDC concurrently
with other bacteria and/or viruses.
Bb belongs to the genusBordetella together withBor-
detella pertussis and Bordetella parapertussis, which cause
whooping cough in man (reviewed by Mattoo and
Cherry, 2005). Of the three species, only Bb survives
in the environment and appears to be able to spread
through amoeba (Taylor-Mulneix et al., 2017). On
entering a mammalian host, the bacterium expresses
virulence factors including adhesins such as filamen-
tous haemagglutinin (FHA), pertactin, tracheal colo-
nization factor and fimbriae that facilitate adhesion to
host cells (Edwards et al., 2005), and toxins, such as
adenylate cyclase haemolysin, dermonecrotic toxin
and tracheal cytotoxin that damage the ciliated
epithelium (Bock and Gross, 2001). The signals for
the in-vivo change from the ‘environmental’ to the
‘host’ phase are unknown. In vitro, however, growth
at 37C was determined to be a trigger.
Bb is a common pathogen and able to cause
CIRDC without the help of respiratory viruses
(Schulz et al., 2014b; Viitanen et al., 2015). The
incubation time is between 2 and 10 days (Bemis
et al., 1977). Affected animals develop a dry parox-
ysmal cough, nasal discharge and, only in severe
cases, depression, pneumonia and death. The
morbidity is high, but the disease is rarely fatal. His-
topathology has shown that infection is limited to
the ciliated mucosa where an inflammatory response
with an influx of polymorphonuclear cells can be
observed (Thompson et al., 1976; Bemis et al., 1977).
Through adhesion to the cilia and the excretion of
toxins the bacterium is thought to cause ciliostasis
and failure of mucociliary clearance (Woolfrey and
Moody, 1991). Disease duration varies from a few
days in mild cases to weeks or longer in more severely
affected dogs (Thompson et al., 1976; Canonne et al.,
2016). Bb is shed from the respiratory tract of
infected animals for a variable length of time,
sometimes many months. Immunity to Bb involves
the local mucosal production of specific
immunoglobulin (Ig) A and IgG antibodies,
although serum IgG responses are also made and
these are more readily used to monitor the efficacyof vaccination in an experimental setting (Chalker
et al., 2003b). Treatment includes antibiotics that
reach therapeutic concentrations in the respiratory
tract (Datz, 2003).
CAV-2 is an non-enveloped DNA virus belonging
to the family Adenoviridae. The virus is highly related
to canine hepatitis virus (CAV-1) and shares approx-
imately 75% of the nucleotide sequence (reviewed by
Buonavoglia and Martella, 2007). CAV-2 is limited
to the respiratory tract and to a lesser degree the intes-
tinal epithelium, while CAV-1 causes systemic infec-
tion. There is one report of the molecular detection
of CAV-2 in the brain of a puppy with neurological
signs (Benetka et al., 2006), but in this case no histo-
pathological changes were detected in the brain sug-
gesting viral pathology.
CAV-2 was first isolated from a dog with laryngo-
tracheitis in Canada in 1961 (Ditchfield et al.,
1962). It is endemic worldwide and its hosts include
wild carnivores and marine mammals. On entry
into the host via droplets, non-ciliated epithelial cells
of the upper respiratory tract become infected. Viral
replication peaks after 3e6 days and then declines
as host immunity develops. Infection with CAV-2
alone is generally mild and self-limiting, but can be
complicated by co-infections. Immunity to CAV-1
cross-protects against CAV-2 and vice versa. Neutral-
izing antibody levels correlate with protection and
can be used to evaluate the need for vaccination.
CDV is an enveloped negative sense single-
stranded RNA virus belonging to the family Para-
myxoviridae in the genus Morbillivirus, together with
measles virus (reviewed by Martella et al., 2008),
and usually causes severe systemic disease in carni-
vores. CDV initially replicates in lymphoid cells of
the respiratory tract before disseminating throughout
the body 3e4 days after infection. This viraemic
phase is characterized clinically by fever. The virus
then infects andmultiplies in epithelial cells of various
organs and the central nervous system (CNS) (Elia
et al., 2015). From 10 days after infection, respiratory,
gastrointestinal and/or dermatological signs are
observed such as ocular and nasal discharge, dysp-
noea, diarrhoea, vomiting and hyperkeratosis of the
foot pads.
If the virus cannot be contained by the immune
response, neurological signs due to demyelination
may also be observed from 20 days after infection
(Gillespie and Rickard, 1956). Neurological signs
generally become progressively worse, as the virus is
able to persist in the CNS. A rare neurological manifes-
tation of CDV infection is ‘old dog encephalitis’, which
is observed in vaccinated adult dogs. It is thought that
the virus is able topersist in theCNS following infection
despite thedevelopment of immunity anddoesnot start
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and Krakowka, 1998).
Distemper can be challenging to diagnose if clinical
signs are notmultisystemic (Chvala et al., 2007). Lym-
phopenia is a characteristic aspect of CDV infection
that is normally not shared by the other respiratory
pathogens. Immunity against CDV is fully protective
and long lasting (Schultz et al., 2010). Neutralizing
antibody levels correlate with protection and can be
used to evaluate the need for vaccination.
CHV is an enveloped DNA virus belonging to the
family Herpesviridae and was first identified as a
canine pathogen in 1965 (Carmichael et al., 1965).
Its host range is restricted to canids. The virus causes
fetal or perinatal death if infection of immunologically
na€ıve animals occurs during pregnancy or shortly af-
ter birth (reviewed by Buonavoglia and Martella,
2007; Evermann et al., 2011). In pups over 2 weeks
of age and adult dogs, clinical signs are rarely
observed following infection. The sites of entry are
the respiratory and genital tracts. From there the
virus moves to the sensory ganglia and becomes
latent. If immunity wanes due to stress, disease,
immunosuppressive therapy, pregnancy or old age,
the virus is reactivated and starts shedding from
many mucosal surfaces. Reactivation normally does
not cause clinical signs, but in some individuals it
has also been implicated in CIRDC, ocular disease,
reproductive disorders, genital lesions and even sys-
temic disease (Kumar et al., 2015).
Influenza A viruses are negative sense segmented
single-stranded RNA viruses belonging to the family
Orthomyxoviridae (reviewed by Buonavoglia and
Martella, 2007). There are different viruses for each
species and these usually only spread within the spe-
cies; however, some subtypes are able to cross between
species. The virus is enveloped so is not stable for long
in the environment and contains eight separate gene
segments, which facilitate the exchange of segments
between different strains in a process called re-
assortment. Strains are identified and classified by
their surface protein subtypes, haemagglutinin (H1
to H16) and neuraminidase (N1 to N9).
Historically, dogs were considered resistant to
influenza infection. In 2004, however, CIV was de-
tected in greyhounds in Florida following repeated
outbreaks of respiratory disease over a number of
years (reviewed by Harder and Vahlenkamp, 2010).
The virus is transmitted from dog to dog, and seropre-
valence can be as high as 49% in the USA. The orig-
inal Florida isolate was a H3N8 subtype and stemmed
from an equine influenza strain that circulated in the
USA in the early 1990s. Another CIV, subtype
H3N2, has been circulating among dogs in south-
eastern Asia since 2007, with a seroprevalence of upto 33%.H3N2CIV has also been associated with out-
breaks of respiratory disease in dogs in the USA since
2015 (Voorhees et al., 2017). These two influenza A
subtypes are unique in that they are both efficiently
transmitted horizontally among co-mingled dogs
and both cause respiratory disease in susceptible
dogs, with morbidity rates as high as 80%. Canine in-
fections with other subtypes (e.g. H5N1, H1N1 and
H3N1) have been reported sporadically, but only
rarely associated with respiratory disease.
Following experimental infection, CIV causes
inflammation and necrosis of the ciliated epithelium
of the respiratory tract as well as in the major organs
(Castleman et al., 2010). Morbidity can reach 100%
and is usually characterized by upper respiratory dis-
ease with fever for 10e14 days. In a minority of dogs,
peracute death due to haemorrhagic bronchopneu-
monia has been described following CIV infections
that were complicated by bacterial co-infections
(Yoon et al., 2005). The severity of the infection de-
pends on the challenge CIV strain. Inactivated virus
vaccines (monovalent or bivalent) have been pro-
duced to protect dogs against H3N8 and H3N2 influ-
enza A virus infection (Parrish and Huber Voorhees,
2019).
CPiV belongs to the family Paramyxoviridae, sub-
family Rubulavirinae, comprising also distantly
related human parainfluenza viruses 2 and 4, and
mumps virus (reviewed by Ellis and Krakowa, 2012;
ICTV, 2018). Although the virus is generally still
referred to as CPiV in veterinary medicine, the
correct nomenclature evolved from ‘parainfluenza
virus 5’ (Rima et al., 2014) to ‘mammalian orthorubu-
lavirus 5’, and this name is consistent with the isolation
of the virus from variousmammals, includingman and
dogs (ICTV, 2018). The virus is highly contagious and
therefore endemic worldwide. It was first isolated
together with other pathogens in 1967 from laboratory
dogs with respiratory disease. Transmission occurs via
droplets. Morbidity depends on the density of the dog
population as the virus does not survive for long in the
environment. The site of entry is the respiratory tract.
CPiV is known to mainly affect the surface epithelium
of the respiratory tract and to rarely cause systemic
infection (Appel and Binn, 1987). Clinical signs
involve mild respiratory signs 2e8 days after infection
that last less than a week unless the disease is compli-
cated by other pathogens (Viitanen et al., 2015).
Very young, geriatric or immunocompromised dogs
may also show systemic signs. There are occasional re-
ports of CPiV being isolated from tissues outside the
respiratory tract, but these are exceptions (Binn et al.,
1979; Buonavoglia and Martella, 2007). It is
assumed that immunity to CPiV involves local
mucosal production of specific antibody, but most
90 M.J. Day et al.published studies measure systemic antibody responses
(Ellis and Krakowa, 2012). Mucosal and parenteral
CPiV vaccines are available.
CnPnV belongs to the family Pneumoviridae, a
new virus family related to the family Paramyxoviri-
dae, which includes CDV and CPiV. In the genusOr-
thopneumovirus, CnPnV is closely related to human
respiratory syncytial virus and bovine respiratory
syncytial virus. CnPnV was first isolated in the USA
from kennelled dogs with respiratory disease in 2010
and has since been detected in Europe (Renshaw
et al., 2010; Mitchell et al., 2013; Decaro et al.,
2016). Little is known about the pathogenesis of
CnPnV infection in dogs. Experimental infection of
mice showed that CnPnV replicated in lung tissue
and caused lethal disease at higher doses; infection
induced antibody responses and protective
immunity (Percopo et al., 2011).
CRCoV was first isolated from the respiratory tract
of dogs with CIRDC from a UK shelter (Erles et al.,
2003) and is a relatively new addition to the possible
causes of CIRDC. It is an enveloped single-stranded
positive RNA virus and belongs to the family Corona-
viridae, genus Betacoronavirus, which also includes
bovine coronavirus and human coronavirus, impli-
cated in shipping fever and severe acute respiratory
syndrome (SARS), respectively. CRCoV is genetically
distinct from canine enteric and pantropic alpha coro-
navirus. CRCoV is probably transmitted via droplets
and initially infects ciliated epithelial cells in the tra-
chea and lymphoid cells of the tonsils (reviewed by
Priestnall et al., 2014). This leads to reduction inmuco-
ciliary clearance and facilitates secondary infections.
Infected dogs show the typical signs of CIRDC and
shed infectious virus for up to 6 days.
Mycoplasma spp. lack a bacterial cell wall and are
thus distinct from other bacteria (reviewed by
Chalker et al., 2004). They are difficult to grow in cul-
ture and consequently are often underdiagnosed. To
date, there are 15 species of Mycoplasma found in
dogs andmanymore have been described in other an-
imals and man.Mycoplasma spp. are normal commen-
sals of the upper respiratory tract, which has
complicated investigations into their virulence. M.
cynos was first described in 1972 following isolation
from the lungs of a dog with pneumonia. Since then
M. cynos has been detected in many other cases of
CIRDC, often concurrently with viral infections, con-
founding the interpretation of its role in the pathogen-
esis of CIRDC (reviewed by Priestnall et al., 2014;
Maboni et al., 2018). However, Zeugswetter et al.
(2007) reported an outbreak of M. cynos mono-
infection in a litter of 3-week-old golden retriever
pups and a recent study supports the role of M. cynosas a primary pathogen in the lower respiratory tract
(Jambhekar et al., 2019).
S. zooepidemicus is a b-haemolytic Lancefield group
C streptococcus. It is part of the normal bacterial flora
of the upper respiratory tract and lower genital tract
of horses (reviewed by Priestnall and Erles, 2011).
The bacterium also causes opportunistic infections
in horses (e.g. abscesses, endometritis) and dogs. Spo-
radic illness resembling CIRDC as well as outbreaks
of often lethal haemorrhagic pneumonia have been
observed. Kennelled dogs are at particular risk of per-
acute outbreaks (Priestnall et al., 2014).
The pathogenesis of S. zooepidemicus infection is
thought to involve exotoxins, which act as superanti-
gens and significantly augment the host immune
response, comparable with human streptococcal toxic
shock syndrome. Although S. zooepidemicus has zoo-
notic potential, transmission from horses or dogs to
man is rarely reported. Experimental challenges
with S. zooepidemicus only caused clinical disease if
dogs were challenged concomitantly with CIV,
underlining the complexity of the interactions be-
tween the different pathogens of CIRDC (Priestnall
et al., 2014).
To better understand the role of the different path-
ogens in the development of CIRDC and their epide-
miological relevance in Europe, prevalence data were
collected from peer-reviewed publications and sum-
marized. These data included serological findings
and detection or isolation results from healthy dogs
and dogs with respiratory disease published since
the year 2000. The literature was searched using Goo-
gle and PubMed databases from 2000 to 2019 with
search terms including: ‘dog’, ‘canine’, ‘respiratory
disease’, ‘respiratory pathogen’ and the names of the
specific organisms described in this review.Prevalence of CIRDC
The most recent prevalence figures on respiratory dis-
ease in dogs are provided by the Small Animal Veter-
inary Surveillance Network (SAVSNET), which held
approximately 1.7 million electronic health records
from 227 veterinary practices in the UK (Singleton
et al., 2019). Between January 2018 and February
2019, 0.9% of dogs were presented for respiratory
signs. More detailed information on the consultations
was obtained from a randomly selected subgroup of
2,404 canine patients. This showed that the most
common presenting sign was coughing (68%) and
that the majority of patients were presented for the
first time (52.2%) and after a period of illness of up
to 1 week (47.2%). In 71.2% of cases, the observed
clinical signs were considered to be respiratory in
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approximately 0.64% of dogs presented annually to
veterinary practices. The proportion of dogs with
CIRDC is likely to be lower, as respiratory signs can
also be due to non-infectious causes such as neoplastic
disease, allergic reactions or brachycephaly (O’Neill
et al., 2015).
Similar SAVSNET surveys were performed in
2014e2015 and 2017 (Sanchez-Vizcaino et al., 2016;
Arsevska et al., 2018). The proportion of canine
patients presented for respiratory signs was 1.7% in
2014e2015 and 1.3% in 2017, compared with 0.9%
in 2018. As before, coughing was the main clinical
sign and the majority of dogs had shown the signs
for <1 week.
O’Neill et al. (2014) investigated the prevalence of
disorders in a representative subset of electronic
health records from UK primary-care veterinary
practices (Vet Compass) between 2009 and 2013
with the aim of detecting differences between pure-
bred and crossbred dogs. Records of 3,884 dogs,
mostly purebred (79.4%), were included in the sur-
vey. The prevalence of upper respiratory tract disease
was 5.7% without a significant difference between
purebred (5.6%) and crossbred (6.4%) dogs.
A pet owner survey was performed in 2014 on
43,005 purebred dogs from the UK (Wiles et al.,
2017). The advantage of such studies is that disease
episodes for which no veterinary advice was sought
are included in the dataset. On the other hand, misin-
terpretation is possible as disorders were not always
clinically confirmed. Furthermore, owners may forget
disease episodes as all data are based on memory
recall. Respiratory disease was reported in 2.8% of
dogs, with kennel cough (0.26%), regular reverse
sneezing (0.15%), unspecified respiratory signs
(0.14%) and brachycephalic airway obstruction syn-
drome (0.12%) as the most commonly reported con-
ditions. Boxers were significantly more likely to be
affected by kennel cough than any of the other sur-
veyed breeds.
Adams et al. (2010) reported a mortality rate of
1.2% due to respiratory disease in 15,881 pedigree
dogs between 1994 and 2014. The reported causes
were ‘unspecified disease or failure’ (0.4%), ‘pneu-
monia’ (0.3%), ‘laryngeal paralysis’ (0.2%),
‘choking’ (0.1%), ‘bronchitis’ (0.1%), ‘tracheal
collapse’ (0.1%) and ‘other’ (0.1%). Another client-
based study covering 5,663 dogs between 2005 and
2014 found no mortality due to respiratory disease
(Lewis et al., 2018). These findings indicate that respi-
ratory disease is rarely lethal in the pet dog popula-
tion.
CIRDC prevalence data from other European
countries are sparse. Balboni et al. (2014) selectedhealth data on 51 client-owned dogs at a teaching
hospital in Italy in 2012. Cases were included in the
study if owners agreed to have their pets sampled
non-invasively (i.e. rectal swabs and spontaneous uri-
nary samples). The majority of dogs were adults
(76%) and purebred (71%). Just over half of the
sampled dogs showed no clinical signs (55%). Respi-
ratory signs were observed in 7.8% of dogs.
A Danish study from 1997 collected, among other
information, health data on 4,295 purebred dogs
registered with the Danish Kennel Club
(Proschowsky et al., 2003). Nearly 11% of dogs had
shown a respiratory disease event during their life-
time, but the responses were not validated by a veter-
inarian.Male dogs were significantlymore likely to be
affected by respiratory disease (12.2%) than female
dogs (9.6%), as were some breeds, including Schnau-
zer (17.9%), scent hounds (17.5%) and sighthounds
(16.4%).
The prevalence of CIRDC is expected to be
higher in kennels where the risk of infection is
increased due to turnover of animals, intensive
housing and stress (Pesavento and Murphy,
2014). Chalker et al. (2003a) investigated CIRDC
in a rehoming kennel and found respiratory signs
in 66% of dogs with 12% of dogs showing severe
signs. The proportion of dogs with CIRDC
increased after arrival at the kennel from 21.1%
in week 1 to >70% in weeks 2e4. After the fourth
week, the proportion of dogs with CIRDC
decreased again.Prevalence of Bordetella bronchiseptica
European publications reporting the prevalence of Bb
in healthy and diseased dogs were reviewed (Table 1).
The seroprevalence of Bb was 22% in healthy, unvac-
cinated adult dogs from Sweden between 2000 and
2001 (Eglund et al., 2003). Exposure rates may even
be higher as exposure does not always result in sero-
conversion and antibody titres decline over time if
not boosted through repeated infections (Jacobs
et al., 2005).
Bacterial isolation from healthy dogs ranged from
0.0% to 45.6% in Austria, Germany and Belgium be-
tween 2009 and 2016 (Schulz et al., 2014b; Stejskal
et al., 2017; Canonne et al., 2018). The variability
may be explained by the different samples collected
in the different studies. Bb is known to reside in the
upper respiratory tract of healthy animals
(Gueirard et al., 1998) so the lack of detection by
Stejskal et al. (2017), in which nasal and pharyngeal
swabs were analysed by both culture and PCR, is sur-
prising. Isolation from the lower respiratory tract is
usually associated with disease (Thompson et al.,
Table 1
Prevalence of Bordetella bronchiseptica in European studies 2000e2019
Country Year Population Method Detection rate Reference
Sweden 2000e2001 302 healthy, non-
vaccinated dogs$2 years
old
Bb specific IgG in serum
by ELISA
22.0% Eglund et al. (2003)
Germany 1989e2011 493 dogs with CIRDC Bb in BALF by culture 5.2% Rheinwald et al. (2015)
Austria 1997e2007 68 dogs with pneumonia Bb in lung samples by
IHC
14.7% Woehrer et al. (2016)
Germany 2004e2009 84 dogs with CIRDC Bb in BALF by culture 20.2% Steinfeld et al. (2012)
EU 2008e2010 215 dogs with CIRDC Bb by culture 22.8% Morrissey et al. (2016)
Italy Not recorded 50 dogs with CIRDC Bb in throat swabs by
RT-PCR
52.0% Corona et al. (2013)
Germany 2011e2012 61 dogs with CIRDC
90 healthy dogs





Schulz et al. (2014b)
Italy 2011e2013 78 dogs with CIRDC Bb in nasal and
pharyngeal swabs by
RT-PCR
10.3% Decaro et al. (2016)
Austria 2013e2015 214 dogs with CIRDC
50 healthy dogs
Bb in nasal and throat




Stejskal et al. (2017)
Poland 2014e2015 40 dogs with CIRDC Bb in URT swabs and
tracheal fluid by PCR
30.0% Kaczorek et al. (2016)
Belgium 2009e2016 24 dogs with eosinophilic
bronchopneumonia
21 dogs with chronic
bronchitis
15 healthy dogs
Bb in BALF by qPCR 25.0%
10.0%
13.0%
Canonne et al. (2018)
UK 2016e2019 1,602 canine respiratory
samples
Bb in samples by qPCR 12.9e17.3% Singleton et al. (2019)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, canine infectious respiratory disease complex; ELISA, enzyme linked
immunosorbent assay; EU, European Union; IHC, immunohistochemistry; PCR, polymerase chain reaction; qPCR, quantitative PCR; RT-
PCR, reverse transcriptase PCR; UK, United Kingdom; URT, upper respiratory tract.
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bronchoalveolar lavage fluid (BALF) samples from
healthy dogs used by Canonne et al. (2018).
The detection rates of Bb in dogs with respiratory
disease were also variable and ranged from 3.3% to
78.7%. An unusually low detection rate was reported
by Stejskal et al. (2017), suggesting perhaps a high
threshold of detection in their assays. Rheinwald
et al. (2015) detected Bb in 5.2% of BALF samples
from dogs with CIRDC in Germany, the second
lowest detection rate of all listed studies. In this retro-
spective study, microbiology results of 493 dogs with
signs of respiratory disease were reviewed for isolation
of Bb over 22 years (1989e2011). In contrast, there
was a detection rate of 78.7% reported for Bb in a sub-
sequent study at the same institution by Schulz et al.
(2014b). Samples for this study were collected over
a 12-month period from 2011 to 2012, which may
have been a time of unusually high Bb prevalence in
the South of Germany. Another reason may have
been the lower age of the sampling population (me-dian 3.5 years, range 3 monthse16 years) compared
with a median of 6 years in the study by Rheinwald
et al. (2015) and the more sensitive detection method.
Against expectations, dogs from private households
were significantly more likely to be infected with Bb
than dogs from shelters in the study by Schulz et al.
(2014b).
The second highest detection rate was reported in
an Italian study of 50 diseased dogs (Corona et al.,
2013). A total of 52% of dogs with CIRDC tested pos-
itive for Bb. Of these, 76% (13/17) of the samples
collected from dogs <1 year of age were positive for
Bb, 44% (8/18) of the samples collected from dogs be-
tween 1 and 7 years of age were positive for Bb and
33% (5/15) of the samples collected from dogs >7
years of age were positive for Bb.
Bb was detected in dogs with pneumonia (14.7%,
Woehrer et al., 2016), eosinophilic bronchopneu-
monia (25%) and chronic bronchitis (10%)
(Canonne et al., 2018). Woehrer et al. (2016) found
Bb together with Pasteurella multocida in five puppies:
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and in another puppy concurrently with CRCoV
and M. canis. Bb was also detected in five adult
dogs, two of which showed concurrent infection
with P. multocida. The findings confirm that Bb partic-
ipates in lung infections, but can also be the sole path-
ogen, even in adult dogs.
The latest UK survey on the prevalence of Bb re-
ported a detection rate of 14.5% in respiratory sam-
ples (Singleton et al., 2019). The survey included
1,602 canine samples that had been analysed by
four laboratories in the UK over a 3-year period
from January 2016 to February 2019. The greatest
proportion of positive samples was found in winter
(17.3%), followed by summer (14.1%), autumn
(13.6%) and spring (12.9%). Spatial trends could
not be detected as areas with high and low propor-
tions of positive samples were observed all over the
UK.
In summary, evidence of exposure to Bb is
frequently found in healthy and diseased dogs and
client-owned dogs are as likely to be infected as ken-
nelled dogs. Co-infections with viral pathogens are
common. Bb was also found in respiratory diseases
that are not typically part of the CIRDC spectrum.
The findings confirm that the pathogen is still an
important cause of CIRDC in Europe.Table
Prevalence of canine adenovirus type
Country Year Population
UK Not recorded 95 vaccinated shelter dogs CAV-
sam
Austria 1997e2007 68 dogs with pneumonia








Italy 2012 Four dogs with
respiratory signs
28 healthy dogs




Italy 2011e2013 78 dogs with CIRDC CAV-2
sw
Finland 2011e2013 20 dogs with
bacterial pneumonia
13 dogs with chronic
Bb infection
CAV-2 in
Poland 2014e2015 40 dogs with CIRDC CAV-
trachea
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CAV-2, c
complex; ISH, in-situ hybridization; PCR, polymerase chain reaction; R
upper respiratory tract.Prevalence of Canine Adenovirus Type 2
European publications reporting the prevalence of
CAV-2 in healthy and diseased dogs were reviewed
(Table 2). Two investigations assessed the presence
of CAV-2 in the respiratory tract of healthy dogs or
dogs with clinical signs other than respiratory signs
in Germany (Schulz et al., 2014a,b) and Italy
(Balboni et al., 2014). Schulz et al. (2014b) found
CAV-2 in only one healthy dog (1.1%), while
Balboni et al. (2014) detected CAV-2 in half of the
healthy dogs and 63.2% of the dogs with clinical
signs. Vaccination status was unlikely to explain the
high prevalence in healthy Italian dogs since >90%
of the study population was vaccinated.
The same group reported a 100% prevalence of
CAV-2 in dogs with respiratory signs, but the number
of diseased dogs in the study was small (n ¼ 4) and
samples had been collected within a 5-week period
during early summerwhenCAV-2was perhaps circu-
lating in the local dog population (Balboni et al.,
2014). Moreover, the samples analysed in this study
were faecal swabs and urine samples, which are not
the traditional sources for CAV-2 detection. The virus
is mainly found in the respiratory tract and
associated lymphoid tissues, although detection in
faeces is reported (Hamelin et al., 1985; Macartney
et al., 1988).2
2 in European studies 2000e2019
Method Detection rate Reference
2 in tracheal and lung
ples by RT-PCR
0.0% Erles et al. (2004)
CAV-2 in lung
samples by ISH
0.0% Woehrer et al. (2016)
-2 in nasal and tonsil
abs by RT-PCR
0.5% Hiebl et al. (2019)




Schulz et al. (2014b)
2 in rectal swabs and




Balboni et al. (2014)
in nasal and pharyngeal
abs by RT-PCR
0.0% Decaro et al. (2016)
BALF/TTW by RT-PCR 0.0%
0.0%
Viitanen et al. (2015)
2 in URT swabs and
l lavage fluid by PCR
0.0% Kaczorek et al. (2016)
anine adenovirus type 2; CIRDC, canine infectious respiratory disease
T-PCR, reverse transcriptase PCR; TTW, transtracheal wash; URT,
Table 3
Prevalence of canine distemper virus in European studies 2000e2019
Country Year Population Method Detection rate Reference
Austria 1997e2007 68 dogs with pneumonia CDV in lung samples by
IHC
16.2% Woehrer et al. (2016)
Austria 2013e2015 214 dogs with CIRDC
50 healthy dogs
CDV in nasal and tonsil
swabs by PCR
0.5% Hiebl et al. (2019)
Germany 2011e2012 61 dogs with CIRDC
90 healthy dogs





Schulz et al. (2014b)
Italy 2011e2013 78 dogs with CIRDC CDV in nasal and
pharyngeal swabs by
RT-PCR
0.0% Decaro et al. (2016)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection




Viitanen et al. (2015)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CDV, canine distemper virus; CIRDC, canine infectious respiratory disease com-
plex; IHC, immunohistochemistry; RT-PCR, reverse transcriptase polymerase chain reaction; TTW, transtracheal wash.
94 M.J. Day et al.In general, CAV-2 recovery rates from healthy and
diseased dogs were low and the most likely explana-
tion for this is control through vaccination. Erles
et al. (2004) did not detect CAV-2 in a shelter dog
population where all dogs were vaccinated on arrival.
Another explanation could be the short period of viral
shedding following infection (Buonavoglia and
Martella, 2007), which may hamper detection unless
samples are collected at onset of clinical signs.Prevalence of Canine Distemper Virus
European publications reporting the prevalence of
CDV in healthy and diseased dogs were reviewed
(Table 3). Reports into the prevalence of CDV in
healthy dogs or dogs with CIRDC were sparse. In
Germany (Schulz et al., 2014b) and Finland
(Viitanen et al., 2015) neither healthy dogs nor dogs
with CIRDC were infected with CDV. Woehrer
et al. (2016) found CDV in 16.2% of Austrian dogs
with pneumonia when investigating historical sam-
ples by immunohistochemistry. All CDV-positive
dogs were #12 months of age and many had concur-
rent neurological and/or gastrointestinal signs. Di
Francesco et al. (2012) reported a CDV prevalence
of 56.6% in Italian dogs that suffered from respiratory
signs coupled with neurological and/or gastrointes-
tinal signs. An investigation into a CDV outbreak
amongst dogs imported from Hungary in 2015
showed that seven of 11 dogs with distemper had clin-
ical signs involving at least two organ systems, mainly
the gastrointestinal and respiratory tracts (Willi et al.,
2015). Even if CDV is rarely diagnosed in dogs in Eu-
rope, the infection remains in the wild population, asfor example in foxes (Garigliany et al., 2018), with a
constant risk of infection of the canine population.
These findings suggest that CDVusually causes sys-
temic disease, but distemper presenting mainly as res-
piratory disease has been described (Chvala et al.,
2007). CDV involvement in CIRDC appears to be
rare due to vaccination. Mitchell et al. (2017) showed
that vaccination against CDV was associated with a
significantly lower risk of CIRDC and severe respira-
tory signs.Prevalence of Canine Herpesvirus
European publications reporting the prevalence of
CHV in healthy dogs and dogs with respiratory signs
were reviewed (Table 4). CHV has been implicated
as a causative agent of CIRDC because experimental
infections have resulted in respiratory signs (Karpas
et al., 1968; Appel et al., 1969). In Belgium,
approximately half of investigated dogs, including
healthy dogs and dogs with various ailments, were
found to be seropositive (Ronsse et al., 2002). In Ger-
many, Italy, Lithuania and the UK, seropositivity or
PCR positivity ranged from 0.0% to 27.7% in
healthy adult dogs (Erles et al., 2004; Erles and
Brownlie, 2005; Manteufel et al., 2008; Musayeva
et al., 2013; Pratelli et al., 2014; Schulz et al., 2014b;
Bottinelli et al., 2016). In some instances,
seropositivity was higher in kennelled dogs or
increased following a stay at a kennel (Erles et al.,
2004; Erles and Brownlie, 2005; Musayeva et al.,
2013). In Norway, 80% of healthy adult dogs were
seropositive for CHV (Krogenæsa et al., 2012). Sero-
positivity is higher in dogs with reproductive
Table 4
Prevalence of canine herpesvirus in European studies 2000e2019
Country Year Population Method Detection rate Reference
UK Not recorded 211 humanely destroyed
shelter dogs
CHV in tracheal samples by RT-PCR
CHV in lung samples by RT-PCR
12.8%
9.6%
Erles et al. (2004)
UK 2001e2002 54 dogs in kennel (A)
with CIRDC
26 dogs in kennel (B)
with CIRDC
CHV in tonsillar swabs by RT-PCR 0.0%
0.0%
Erles and Brownlie (2005)
Slovakia Not recorded 20 dogs with CIRDC
10 healthy dogs
CHV-specific antibodies in sera by ELISA 60.0%
0.0%
Vojtek et al. (2010)
Germany 2011e2012 90 healthy dogs
61 dogs with CIRDC




Schulz et al. (2014b)
Italy 2011e2013 78 dogs with CIRDC CHV in nasal and pharyngeal swabs by
RT-PCR
0.0% Decaro et al. (2016)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic
Bb infection
CHV in BALF/TTW by RT-PCR 0.0%
0.0%
Viitanen et al. (2015)
Poland 2014e2015 40 dogs with CIRDC CHV in URT swabs and tracheal lavage
fluid by PCR
80.0% Kaczorek et al. (2016)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CHV, canine herpesvirus; CIRDC, canine infectious respiratory disease complex;
ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase PCR; TTW, transtracheal wash;
URT, upper respiratory tract.
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2001; Dahlbom et al., 2009; Cobzariu et al., 2018).
Erles et al. (2004) found CHV in 12.8% of tracheal
samples and 9.6% of lung samples of shelter dogs that
were humanely destroyed because of behavioural
problems or severe (including respiratory) diseases.
The presence of CHV was more likely if dogs had
moderate to severe signs of CIRDC, but this was
not significant. In another study (Erles and
Brownlie, 2005), CHV was not isolated from tonsillar
swabs of dogs from two training kennels, which occa-
sionally had outbreaks of CIRDC; however, there was
seroconversion against CHV following these out-
breaks. Vojtek et al. (2010) investigated the presence
of antibodies against CHV in 20 dogs with CIRDC
and found that 60% were positive, while none of the
healthy control dogs tested seropositive.
Kaczorek et al. (2016) isolated CHV from 80% of
dogs with CIRDC and found that detection was
more successful with tracheal lavage samples than
swabs from the upper respiratory tract. Unfortu-
nately this study did not contain a control population.
Schulz et al. (2014b) failed to find CHV in healthy
dogs and dogs with CIRDC when testing nasal and
pharyngeal swabs. A Finnish study of dogs with bac-
terial pneumonia and chronic bronchitis did not yield
any CHVwhen BALF and transtracheal washes were
tested (Viitanen et al., 2015).
In summary, seroconversion to CHV can be
demonstrated following CIRDC outbreaks and
CHV has been detected in the lower respiratory tractof diseased dogs. Whether CHV is the primary cause
of CIRDC or, as a latent herpesvirus, opportunisti-
cally reactivates at the time of infection with other
pathogens of the complex is unclear. Kaczorek et al.
(2016) found CHV in combination with other patho-
gens in 71.9% of dogs with CIRDC compared with
28.1% of dogs with only CHV. Samples were not
tested for all possible pathogens, leaving doubt as to
whether CHV infection alone induced the clinical
signs. That CHV predominantly plays an exacer-
bating rather than initiating role in CIRDC is corrob-
orated by the findings of Erles et al. (2004) who
detected CHV later than other viral infections in a
shelter population of dogs and in more moderate
and severe cases of CIRDC.Prevalence of Canine Influenza Virus
European publications reporting the seroprevalence
of influenza A viruses in healthy and diseased dogs
were reviewed (Table 5). Apart from an historical
outbreak in theUK (Daly et al., 2008) the reported se-
roprevalence against CIV was low in Europe before
2013. In Italy, up to 3.56% of dogs had antibodies
against CIV (Dundon et al., 2010; Piccirillo et al.,
2010; Pratelli and Colao, 2014). In Germany the
seroprevalence was up to 2.86% (Damiani et al.,
2012; Schulz et al., 2014a). A survey of dogs from
France, Hungary, Italy, Greece, The Netherlands
and Spain showed a seroprevalence of 2.7% by
enzyme-linked immunosorbent assay (ELISA)
Table 5
Prevalence of canine influenza virus in European studies 2000e2019
Country Year Population Method Detection rate Reference
Italy 1997e2011 562 sera from adult dogs CIV-specific antibodies by
cELISA,
124 positive and negative





Pratelli and Colao (2014)
Italy 2004e2008 224 farm and rescue dogs CIV-specific antibodies by
cELISA
0.0% Piccirillo et al. (2010)
Italy 2009 964 sera from healthy dogs CIV-specific antibodies by
cELISA, positive samples re-
tested by H1N1-specific HI
3.0%
0.7%
Dundon et al. (2010)
Germany 2010e2011 736 dog sera CIV-specific antibodies by
cELISA, positive samples re-




Damiani et al. (2012)
Germany 2010e2011 272 healthy dogs 35 dogs with
acute CIRDC
CIV H3N8-specific antibodies
in sera by ELISA
0.37% Schulz et al. (2014a)
Positive samples re-tested by
IFA and subtype-specific HI





Germany 2011e2012 90 healthy dogs
61 dogs with CIRDC




Schulz et al. (2014b)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection




Viitanen et al. (2015)
Italy 2011e2013 78 dogs with CIRDC CIV in nasal and pharyngeal
swabs by RT-PCR
0.0% Decaro et al. (2016)
Austria 2013e2015 214 dogs with CIRDC
50 healthy dogs
CIV in nasal and tonsil swabs by
PCR
0.0% Hiebl et al. (2019)
Europe 2011e2013 525 dogs exposed to CIRDC CIV in URT swabs by RT-PCR
(n ¼ 511)
CIV antibodies in sera by
cELISA (n ¼ 220)
0.0%
2.7%
Mitchell et al. (2017)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, canine infectious respiratory disease complex; CIV, canine influenza
virus; cELISA, competitive enzyme-linked immunosorbent assay; HI, haemagglutination inhibition test; IFA, immunofluorescence antibody
test; RT-PCR, reverse transcriptase polymerase chain reaction; SN, serum neutralization test; TTW, transtracheal wash; URT, upper respiratory
tract.
96 M.J. Day et al.(Mitchell et al., 2017), but re-testing of positive sam-
ples by subtype-specific haemagglutination inhibition
test did not always confirm positivity (Dundon et al.,
2010; Damiani et al., 2012; Pratelli and Colao, 2014;
Schulz et al., 2014b). This could be due to false-
positive results in the ELISA or the presence of
antibodies to subtypes that were not tested for.
In accordance with the low seroprevalence of CIV
in Europe, CIV was not detected in respiratory tract
samples from any tested healthy dog or dog with res-
piratory disease in Europe between 2010 and 2019
(Schulz et al., 2014a, b; Viitanen et al., 2015; Decaro
et al., 2016; Mitchell et al., 2017; Hiebl et al., 2019).
Reasons for this could be the sampling time points
and/or the studied populations. Viral shedding
occurs early after infection for 1e6 days and ismissed if swabs are collected too late (Castleman
et al., 2010). CIV is more likely to circulate in animals
from multi-dog households and kennels (Buonavoglia
and Martella, 2007), which may not have been
included in sufficient numbers in the above studies.
Currently available data suggest that CIV is, at pre-
sent, neither a prevalent nor a significant pathogen
of CIRDC in Europe.Prevalence of Canine Parainfluenza Virus
European publications reporting the prevalence of
CPiV in healthy and diseased dogs were reviewed
(Table 6). CPiV is found commonly in samples of
dogs with and without respiratory signs. Schulz et al.
(2014b) detected CPiV in 7.8% of healthy German
Table 6
Prevalence of canine parainfluenza virus in European studies 2000e2019
Country Year Population Method Detection rate Reference
UK Not recorded 211 humanely destroyed shelter
dogs
150 shelter dogs on arrival
CPiV in tracheal samples by RT-PCR
CPiV in lung samples by RT-PCR




Erles et al. (2004)
Germany 2011e2012 61 dogs with CIRDC
90 healthy dogs




Schulz et al. (2014b)
Italy 2011e2013 78 dogs with CIRDC CPiV in nasal and oropharyngeal swabs by
RT-PCR
20.5% Decaro et al. (2016)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection
CPiV in BALF/TTW by RT-PCR 35.0%
0.0%
Viitanen et al. (2015)
Poland 2014e2015 40 dogs with CIRDC CPiV in URT swabs and tracheal lavage
fluid by PCR
67.5% Kaczorek et al. (2016)
Austria 2013e2015 214 dogs with CIRDC
50 healthy dogs
CPiV in nasal and tonsil swabs by RT-PCR 6.5% Hiebl et al. (2019)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, canine infectious respiratory disease complex; CPiV, canine parain-
fluenza virus; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase PCR; TTW, trans-
tracheal wash; URT, upper respiratory tract.
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tracheal samples and 10.4% of lung samples of dogs
humanely destroyed at a UK shelter. Since 65% of
these dogs showed respiratory signs before humane
destruction, the results cannot be compared directly
with those of a healthy population. The higher detec-
tion rate in tracheal samples (19.4%) compared with
lung samples (10.4%) is characteristic for the virus as
its target tissue is mainly ciliated epithelium of the up-
per respiratory tract (Appel and Binn, 1987).
In dogs with CIRDC or bronchial pneumonia,
CPiV was detected in 6.5%e67.5% of animals
(Schulz et al., 2014b; Viitanen et al., 2015; Decaro
et al., 2016; Kaczorek et al., 2016; Hiebl et al., 2019).
CPiV prevalence in healthy and diseased dogs was
compared in one study and shown to be
significantly higher if dogs had CIRDC (Schulz
et al., 2014b). In contrast, Erles et al. (2004) reported
tracheal CPiV in 20% of dogs without respiratory
signs and 19% of dogs with respiratory signs. The
lack of an association between clinical signs and
CPiV detection in this study can have many explana-
tions. Dogs with pre-existing immunity to CPiV
through vaccination and past exposure may still
become infected with CPiV field strains, but are less
likely to show clinical signs (Emery et al., 1976). Since
44% of the dogs in the study by Erles et al. (2004) had
antibodies against CPiV on arrival at the shelter, they
would have been protected from clinical signs,
although virus shedding may have still occurred.
Another explanation is that dogs with CPiV-positive
samples and without clinical signs were humanely de-
stroyed during an early stage of infection when clin-ical signs were not yet detectable. Furthermore,
close-contact housing in the shelter and circulation
of a field CPiV strain amongst the shelter dogs may
have distorted detection rates in this study.
Decaro et al. (2016) investigated the presence of
CPiV in dogs with acute CIRDC, dogs exposed to
CIRDC and CIRDC convalescent dogs and reported
detection rates of 20.5%, 4.5% and 2.6%, respec-
tively, suggesting that CPiV is more commonly found
in dogs with signs of CIRDC than in dogs without
such signs. Statistical analysis of the association be-
tween a respiratory score and the presence of CPiV
approached significance in this study (P ¼ 0.063).
In another study, approximately one third of dogs
with bacterial pneumonia carried CPiV (Viitanen
et al., 2015). The authors speculated that initial infec-
tion with CPiVmay predispose dogs to lung infections
with opportunistic bacteria. Kaczorek et al. (2016) re-
ported the highest prevalence of CPiV in dogs with
CIRDC of 67.5%, but no healthy control group was
included in this study.
CPiV infection was often accompanied by the pres-
ence of other pathogens. Common combinations
were: (1) CPiV with Bb, which occurred more often
in dogs with CIRDC than in healthy dogs
(P <0.001, Schulz et al., 2014b), (2) CPiV with
CRCoV (Erles et al., 2004; Schulz et al., 2014b;
Decaro et al., 2016), and (3) co-infection with CAV-
2 and/or CHV (Erles et al., 2004; Kaczorek et al.,
2016).
Therefore, there is evidence to support CPiV as still
being an important pathogen in CIRDC in Europe,
despite widespread vaccination. Furthermore, CPiV
Table 7
Prevalence of canine pneumovirus in European studies 2000e2019
Country Year Population Method Detection rate Reference

















Mitchell et al. (2013)
Italy 2011e2013 78 dogs with CIRDC CnPnV in nasal and
oropharyngeal swabs by RT-
PCR
6.41% Decaro et al. (2016)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection




Viitanen et al. (2015)
EU 2011e2013 525 dogs exposed to CIRDC CnPnV in URT swabs by
RT-PCR (n ¼ 511)
CnPnV antibodies in sera by
ELISA (n ¼ 220)
23.4%
41.7%
Mitchell et al. (2017)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, canine infectious respiratory disease complex; CnPnV, canine pneumo-
virus; ELISA, enzyme-linked immunosorbent assay; RT-PCR, reverse transcriptase polymerase chain reaction; TTW, transtracheal wash; URT,
upper respiratory tract.
98 M.J. Day et al.appears to facilitate co-infection with other viral and
bacterial pathogens.Prevalence of Canine Pneumovirus
European publications reporting the prevalence of
CnPnV in healthy and diseased dogs were reviewed
(Table 7). CnPnV was discovered as a causative
agent of CIRDC in the USA in 2010. Since then, its
prevalence in Europe has also been confirmed
(Mitchell et al., 2013, 2017; Decaro et al., 2016).
Mitchell et al. (2013) analysed 625 canine serum sam-
ples from the UK and Ireland for antibodies against
CnPnV and found that 50.2% were seropositive. A
Europe-wide study including France, Greece,
Hungary, Italy, The Netherlands and Spain
confirmed that CnPnV was also circulating in these
countries (Mitchell et al., 2017). Seroprevalences var-
ied considerably between countries with France
showing the highest prevalence of 70.1% followed
by The Netherlands (60.3%), Hungary (43.3%),
Spain (37.7%), Greece (27.1%) and Italy (21.5%).
Infection with CnPnV appears to occur from 6
months of age onwards as dogs <6 months were sero-
negative (Mitchell et al., 2013). Seronegative dogs
convert within 3 weeks of arrival at a kennel, indi-
cating that housing dogs in close proximity facilitates
the spread of CnPnV (Mitchell et al., 2013). Mitchell
et al. (2017) showed that the seroprevalence of CnPnVwas significantly higher in shelter dogs (54.8%) than
inclient-owned dogs (21.8%).
Dogs that seroconverted against CnPnV following
entry into a kennel were significantly more at risk of
developing CIRDC and significantly more likely to
show severe disease than dogs that had pre-existing
antibodies (Mitchell et al., 2013, 2017). Decaro et al.
(2016) found a lower prevalence of CnPnV in dogs
with CIRDC (6.41%) than Mitchell et al. (2017;
22.2%) and no association with severe clinical signs.
The differences may be explained by the higher pro-
portion of client-owned dogs in the former study.
CnPnV was not detected in dogs with bacterial pneu-
monia or chronic Bb infections (Viitanen et al., 2015),
suggesting that CnPnVdoes not play a significant role
in these more chronic respiratory diseases.
Decaro et al. (2016) found co-infections of CnPnV
with CRCoV or Bb and M. canis in two of five dogs
(40%) in Italy. Kennelled dogs in the UK showed
co-infection of CnPnV with CRCoV and/or CPiV
in 69.5% of cases (Mitchell et al., 2013). Mitchell
et al. (2017) were able to demonstrate that the pres-
ence of CRCoV doubled the likelihood of a positive
result for CnPnV. Therefore, CnPnV can be consid-
ered as an important new pathogen in CIRDC, often
found in co-existence with CRCoV. CnPnV spreads
particularly well in multi-dog establishments. Expo-
sure appears to result in protective immunity against
clinical signs suggesting that vaccination may be
effective against this pathogen.
Table 8
Prevalence of canine respiratory coronavirus in European studies 2000e2019
Country Year Population Method Detection rate Reference
Austria 1997e2007 68 dogs with pneumonia CRCoV in lung samples by
RT-PCR
15.6% Woehrer et al. (2016)
Austria 2013e2015 214 dogs with CIRDC
50 healthy dogs
CRCoV in nasal and tonsil
swabs by RT-PCR
7.5% Hiebl et al. (2019)
Italy 1999e2006 590 dog sera CRCoV-specific antibodies
in serum by ELISA




109 canine lung samples
CRCoV-specific antibodies
by ELISA




Decaro et al. (2007)
Italy 2011e2013 78 dogs with CIRDC CRCoV in nasal and
oropharyngeal swabs byRT-
PCR
8.97% Decaro et al. (2016)




in sera by ELISA




Erles et al. (2003)
UK 2001e2002 90 kennelled dogs (A)
62 kennelled dogs (B)
64 kennelled dogs (A)
CRCoV-specific antibodies
in blood by ELISA





Erles and Brownlie (2005)
UK and
Ireland
Not recorded 896 dog sera CRCoV-specific antibodies
in serum by ELISA
35.6% Priestnall et al. (2006)
Austria Not recorded 129 client-owned dogs with
CIRDC
CRCoV-specific antibodies
in serum by IFA
CRCoV in oropharyngeal




Germany 2011e2012 61 dogs with CIRDC
90 healthy dogs
CRCoV in nasal and




Schulz et al. (2014b)
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection




Viitanen et al. (2015)
Europe 2011e2013 525 dogs exposed to CIRDC CRCoV in URT swabs by
PCR




Mitchell et al. (2017)
BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, canine infectious respiratory disease complex; CRCoV, canine respira-
tory coronavirus; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescence antibody test; PCR, polymerase chain reaction; RT-
PCR, reverse transcriptase PCR; TTW, transtracheal wash; URT, upper respiratory tract.
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Coronavirus
European publications reporting the prevalence of
CRCoV in healthy and diseased dogs were reviewed
(Table 8). Antibodies to CRCoV were found in Ital-
ian dog samples from 1999 onwards (Priestnall et al.,
2007). The seroprevalence ranged from 8% to 30%
depending on the year. Another Italian study, which
investigated retrospectively the presence of CRCoV
antibodies in canine sera collected between 1994
and 2006, reported positive samples from 2005 on-
wards at a seroprevalence of 38.3% in 2005 and
26.8% in 2006. In the UK, 22.2%e54.2% of dogsshowed antibodies against CRCoV, with consider-
able regional variability (Erles et al., 2003; Erles and
Brownlie, 2005; Priestnall et al., 2006), which
appeared to be correlated to the population density.
Seroprevalence was found to increase with age and
exposure to other dogs. Adult dogs are significantly
more likely to be seropositive for CRCoV than dogs
<1 year of age (Priestnall et al., 2006, 2007).
Presumably this can be explained by increasing
contact with other dogs and therefore a rising risk of
exposure to CRCoV with advancing age. Mitchell
et al. (2017) reported that the seroprevalence in shel-
ter dogs was higher (55.6%) than in client-owned
100 M.J. Day et al.dogs (36.7%). Following arrival at a kennel, the ma-
jority of seronegative dogs seroconverted within 3
weeks, so that the seroprevalence in some kennels
reached nearly 100% (Erles et al., 2003; Erles and
Brownlie, 2005).
When the seroprevalence for CRCoV was moni-
tored in two kennels for 2 years, it was found that sero-
conversion was often preceded by an outbreak of
CIRDC (Erles and Brownlie, 2005). Seronegative
dogs had a significantly higher risk of developing
CIRDC following arrival than seropositive dogs
(Erles et al., 2003). Furthermore, CRCoV isTable
Prevalence of Mycoplasma species
Country Year Population
Slovenia 2008e2013 34 healthy dogs M spp. in
M spp. sp
UK Not recorded 42 dogs from a shelter M.
seroconv
Austria 1997e2007 68 dogs with pneumonia M spp. in
UK 1999e2002 210 humanely destroyed
dogs from shelter (A)
M spp. in
samples b
2001e2002 153 dogs from training
kennel (B)









16 dogs without respiratory
disease
Italy 2011e2013 78 dogs with CIRDC M. cyn
oropharyn
Finland 2011e2013 20 dogs with bacterial
pneumonia
13 dogs with chronic Bb
infection
M spp. in
EU 2011e2013 525 dogs exposed to CIRDC M spp. i
M. cynos a




Belgium 2009e2016 24 dogs with eosinophilic
bronchopneumonia





BALF, bronchoalveolar lavage fluid; Bb, Bordetella bronchiseptica; CIRDC, c
ing assay; ELISA, enzyme-linked immunosorbent assay; M, Mycoplasma; P
qPCR, quantitative PCR; TTW, transtracheal wash; URT, upper respirafrequently detected in the respiratory tract of dogs
with respiratory disease. Woehrer et al. (2016) found
15.5% of pathological samples from dogs with pneu-
monia contained CRCoV. Some of the positive sam-
ples were co-infected with Bb and/or bacterial
pathogens. Decaro et al. (2007) detected CRCoV in
one dog (0.92%) in Italy that had died of a canine
parvovirus infection. Higher detection rates were
observed by Decaro et al. (2016) when investigating
dogs that were acutely affected by CIRDC (8.97%),
had been exposed to dogs with CIRDC (1.28%) or
were CIRDC convalescent (5.26%). Just under half9
in European studies 2000e2019
Method Detection rate Reference
oral swabs by PCR 2.9% (M. cynos)
11.8% (M. canis)










Rycroft et al. (2007)
lung samples by
RT-PCR
2.9% Woehrer et al. (2016)
BALF and tracheal
y culture and PCR
23.9% (CIRDC)
9.7% (healthy)







Canonne et al. (2016)
. in BALF and




Schulz et al. (2015)
86.7% (pharyngeal)
18.8% (BALF)
os in nasal and
geal swabs byRT-
PCR





Viitanen et al. (2015)
n URT swabs by
PCR




Mitchell et al. (2017)




Stejskal et al. (2017)




9.5% (each M spp.)
13.0% (each M spp.)
Canonne et al. (2018)
anine infectious respiratory disease complex; DIBA, dot-immunobind-
CR, polymerase chain reaction; RT-PCR, reverse transcriptase PCR;
tory tract.
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infections with CPiV, CnPnV, Bb and/or Mycoplasma
species.
Schulz et al. (2014b) found CRCoV in 9.8% of dogs
with CIRDC and in no healthy control dogs. The dif-
ference in detection rates was significant. Further-
more, all CRCoV-positive dogs in that study had
co-infections with Bb. Similar detection rates were ob-
tained for dogs with CIRDC in Austria (8.8%, Spiss,
2012; 7.5%, Hiebl et al., 2019), Greece (8.6%),
Hungary (7.4%), France (11.5%) and The
Netherlands (13.6%) (Mitchell et al., 2017). The
presence of CRCoV was associated with a signifi-
cantly higher risk of developing severe signs of
CIRDC in a European study (Mitchell et al., 2017).
CRCoV is widespread in Europe and more com-
mon where dogs have increased contact with other
dogs. The virus is detected consistently in approxi-
mately 10% of cases with CIRDC and has been
linked to an increase in severity of clinical signs, sug-
gesting that it plays a role in the pathogenesis of
CIRDC.Prevalence of Mycoplasma species
European publications reporting the prevalence of
mycoplasma species in healthy and diseased dogs
were reviewed (Table 9). Data on the seroprevalence
ofMycoplasma spp. in dogs are sparse. Over two thirds
of healthy working dogs in Slovenia were found to
have antibodies against M. cynos and M. canis by
dot-immunobinding assay (Suhadolc Scolten et al.,
2017). In a European study of dogs with CIRDC, se-
roprevalence levels ranging from 20.7% to 61.9%
were noted in different countries (Mitchell et al.,
2017). Western blotting of paired canine serum sam-
ples from a shelter in the UK showed that dogs that
developed respiratory signs were significantly more
likely to seroconvert to M. cynos than dogs that re-Table











Germany 1989e2011 493 client-owned dogs with
respiratory signs
Strepto
Italy 2011e2013 78 dogs with CIRDC S. equi
nasa
s
BALF, bronchoalveolar lavage fluid; CIRDC, canine infectious respiratormained healthy (Rycroft et al., 2007), supporting
the view that M. cynos is associated with CIRDC.
Mycoplasma spp. are frequently detected in respira-
tory samples of healthy dogs. Detection rates in
healthy dogs ranged from 0.9% to 91.7%. Stejskal
et al. (2017) isolated Mycoplasma species from 78% to
93% of throat swabs from healthy dogs, withM. canis
as the predominant species. Schulz et al. (2015)
showed that rates were higher in pharyngeal swabs
than in BALF samples. The findings indicate thatMy-
coplasma spp. are normal commensals of the upper res-
piratory tract.M. cynoswas, however, only detected in
dogs with respiratory disease in both studies.
Others were able to confirm that the presence ofM.
cynos is significantly associated with more severe respi-
ratory signs (Chalker et al., 2004; Decaro et al., 2016)
and that only dogs with high loads of M. cynos were
diseased (Canonne et al., 2018). Chalker et al. (2004)
demonstrated that there is a significant association
between M. cynos infection and young age (<1
year), time spent at a shelter (>1 week) and CIRDC.
Schulz et al. (2015) also showed a notable difference in
the proportion of dogs withMycoplasma spp. in BALF
samples between healthy dogs (18.8%) and dogs with
respiratory signs (37.9%), but the difference was not
significant. Not all dogs with respiratory signs had in-
fectious diseases, as dogs with airway collapse and
reverse sneezing were also included, which may
have reduced the statistical power of the study. Simi-
larly, Canonne et al. (2016) could not demonstrate a
significant difference in the presence of M. cynos be-
tween healthy and diseased dogs. Reasons for this
may have been the small animal number in this study
and antibiotic pre-treatment of diseased dogs, which
may have reduced the number of positive dogs.
Woehrer et al. (2016) foundmycoplasma in 2.9% of
dogs with pneumonia in a retrospective study of histo-
pathological samples. Considerably higher detection
rates were achieved using BALF samples of dogs
with bacterial pneumonia (40%; Viitanen et al.,10
uropean studies 2000e2019
Method Detection rate Reference




Chalker et al., (2003a)
coccus spp. in BALF by
culture




0.0% Decaro et al. (2016)
y disease; RT-PCR, reverse transcriptase polymerase chain reaction.
102 M.J. Day et al.2015), eosinophilic bronchopneumonia (25% M.
canis, 8.3% M. cynos) and chronic bronchitis (8.3%
each M. canis and M. cynos; Canonne et al., 2018).
Stejskal et al. (2017) showed that respiratory signs
were significantly more likely ifM. canis orMycoplasma
spumans were isolated from nasal swabs.
In two studies investigating dogs with Bb infections,
Mycoplasma spp. were also found in 23.1% (Viitanen
et al., 2015) and 53% (M. cynos only, Canonne et al.,
2016) of animals. Schulz et al. (2015) and Decaro
et al. (2016) also found co-infections of M. cynos with
Bb. In the latter study co-infections of M. cynos with
respiratory viruses (CPiV, CRCoV) were also re-
ported.
Therefore, M. cynos is widespread in Europe and
more common in younger dogs and kennelled dogs.
The organism is frequently found in dogs with respira-
tory disease, often together with other CIRDC path-
ogens. M. cynos is significantly associated with more
severe respiratory signs, suggesting that it exacerbates
respiratory infections.Prevalence of Streptococcus species
European publications reporting the prevalence of
streptococcal species in healthy and diseased dogs
were reviewed (Table 10). Rheinwald et al. (2015)
showed that streptococci were themost frequently iso-
lated bacterial species from BALF samples of dogs
with respiratory disease (30.7%). In another study,
S. zooepidemicus was found in 1.4% of BALF samples
from pet dogs with respiratory signs (Chalker et al.,
2003a). Streptococcus canis was not detected in those
dogs, but was occasionally isolated from shelter dogs
that were humanely destroyed (8.0%). Instead, shel-
ter dogs mainly harboured S. zooepidemicus, particu-
larly if they had severe respiratory signs.
Decaro et al. (2016) did not detect S. zooepidemicus in
78 Italian dogs with CIRDC. This is in accordance
with the results of Chalker et al. (2003a) where only
1 of 71 pet dogs tested positive for S. zooepidemicus, sup-
porting the notion that it is not a common pathogen
and may be a particular problem in kennels
(Chalker et al., 2003a).Diagnosis and Control of CIRDC
The diagnosis of CIRDC is usually based on clinical
signs as described above (Singleton et al., 2019). His-
tory of being kennelled or exposure to other dogs with
CIRDC can also point towards CIRDC. Testing of
nasal, oropharyngeal or conjunctival swabs by PCR
for viral and bacterial pathogens and by submission
of samples for bacterial culture may be performed,
but results can be difficult to interpret as many path-ogens may be isolated from healthy and diseased dogs
(Lappin et al., 2017).
Control of CIRDC involves vaccination and
improvement of kennelling conditions, considering
factors such as sanitation, population density, ventila-
tion and quarantine procedures (LeRoith et al.,
2012). Vaccines are available against Bb, CAV-2,
CDV and CPiV. A vaccine is also available against
CHV for use in bitches to prevent mortality in
neonatal puppies. In the case of respiratory vaccines,
vaccination does not always prevent infection and
shedding from the respiratory tract. Immunity
against CDV prevents infection and is therefore
100% protective against CDV involvement in
CIRDC (Wilson et al., 2014). In contrast, immunity
through vaccination against CAV-2 and CPiV re-
duces morbidity and shedding, but does not prevent
field infections (Emery et al., 1976; Kontor et al.,
1981; Wilson et al., 2014).
Vaccination against Bb has been available for
many years. Initially, inactivated vaccines were
administered parenterally with good results (re-
viewed by Ellis, 2015). To improve local immunity,
modified-live intranasal vaccines were introduced,
which showed comparable or improved efficacy to
injectable formulations and were slightly safer (Ellis,
2015). Larson et al. (2013) found that intranasal
vaccination reduced clinical signs, lung pathology
and bacterial shedding following an experimental
challenge, but did not analyse this finding statisti-
cally. Ellis et al. (2016) confirmed that intranasal
vaccination significantly reduced clinical signs and
bacterial shedding compared with non-vaccinated
control animals.
Due to the difficulties associated with intranasal
administration in some dogs, oral vaccination against
Bb was introduced in 2011. Comparative studies be-
tween intranasal and oral formulations have shown
variable results. Larson et al. (2013) found that the
oral route induced higher levels of nasal IgA after
vaccination, and that both vaccination routes equally
reduced clinical signs, lung pathology and bacterial
shedding following an experimental challenge. How-
ever, these findings were not verified statistically. Ellis
et al. (2016) also compared intranasal and oral vac-
cines against Bb. They found that vaccination by
both routes significantly reduced clinical signs, but
that administration by the intranasal route was
more efficacious at reducing bacterial shedding. The
authors concluded that the intranasal formulation
provided better efficacy than the oral formulation
and attributed this to a greater antigen exposure of
local lymphoid tissue following intranasal administra-
tion.
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with the upper respiratory and digestive tracts: the
pharyngeal tonsil in the nasopharynx dorsal to the
auditory tubes, a small lingual tonsil at the base of
the tongue, and the palatine tonsil in the lateral side
of the oropharynx (Casteleyn et al., 2011). The lingual
and palatine tonsils are likely to be exposed to oral
vaccines and the palatine and pharyngeal tonsils are
likely to be exposed to intranasal vaccines. Although
lymphoid tissues are anatomically separated, all sites
of the immune system are functionally connected
through circulating immune cells. This is supported
by the protection provided against respiratory disease
through parentally administered vaccines.
Although vaccines against CAV-2, CPiV and Bb
do not prevent clinical signs and shedding (Emery
et al., 1976; Kontor et al., 1981; Hess et al., 2011;
Wilson et al., 2014; Scott-Garrard et al., 2018), they
still provide epidemiological advantages, reduce
suffering and decrease the need for antibiotic
treatment. The greater and longer the exposure to
respiratory pathogens in the field, the more likely
are infection and clinical disease (Foley et al., 2002;
Mitchell et al., 2013). A reduction in shedding is
therefore likely to result in less environmental
contamination and slow the spread to other dogs.
Field studies utilising intranasal vaccines against
canine respiratory pathogens have demonstrated
that their use leads to a decreased incidence of
CIRDC. Glickman and Appel (1981) found that a
trivalent vaccine containing Bb, CPiV and CAV-2
was 71.2% and 81.8% effective at reducing the inci-
dence of coughing in a Beagle breeding facility during
summer and winter, respectively. Another study
demonstrated that intranasal vaccination in a shelter
setting helped to reduce coughing by 24.4% for a
trivalent vaccine and 20.7% for a bivalent vaccine
(Edinboro et al., 2004). Finally, Mitchell et al.
(2017) were able to demonstrate a significant level
of protection from CIRDC and severe respiratory
signs in dogs vaccinated against CDV, CAV-2 and
CPiV. Others could only demonstrate a non-
significant protective effect following vaccination
against CPiV (Erles et al., 2004; Schulz et al.,
2014b), perhaps because the study populations were
too small to show significant differences.
Examples of vaccines with more significant effects
at the population level than in an individual animal
can be found in management systems where large
numbers of animals are kept in close proximity
(e. g. poultry farms, dairy herds, studs and feedlots).
Theurer et al. (2015) demonstrated through a system-
atic review and meta-analysis that the risk of devel-
oping bovine respiratory disease in the field was
significantly lowered through vaccination againstcausative viruses. Vaccinating horses regularly
against equine herpesvirus (EHV) 1 and EHV 4,
and equine influenza virus, is recommended as vacci-
nation is currently considered the most effective con-
trol method in the field (Reed and Toribio, 2004;
Lunn et al., 2009), even though vaccines against
EHV1 have been found to only reduce clinical signs
and shedding (Burrows et al., 1984).
Another epidemiological benefit of vaccination
against CAV-2, CPiV and Bb involves spread of
attenuated vaccine strains to non-vaccinated in-
contact dogs. Vaccinated dogs shed vaccine strains
for a variable duration after vaccination (Ruch-
Gullie et al., 2016). Shedding can interfere with the
diagnosis of field infection as the strains cannot usu-
ally be distinguished. An obvious advantage of vac-
cine strain shedding, however, is the spread to other
in-contact dogs and stimulation of their immune sys-
tems to develop immunity or augment existing pro-
tection. Since the vaccine strains are attenuated,
they do not usually cause disease in na€ıve in-contact
dogs (Zoetis, data on file). Therefore, immunity in
the canine population can be increased directly
through vaccination and indirectly through contact
of non-vaccinated dogs with vaccinated dogs.
Apart from epidemiological advantages, vaccina-
tion against CIRDC pathogens is directly beneficial
for the dog as it reduces the occurrence of CIRDC
and the severity of clinical signs (Mitchell et al.,
2017). A reduction in clinical signs positively affects
the welfare of the pet and its owner and will influ-
ence the length of antibiotic treatment prescribed.
Antimicrobial use in animals can contribute to the
emergence of resistant bacteria that can be trans-
ferred to people through direct contact. This may
reduce the effectiveness of antimicrobials for treating
human and animal diseases (Edo et al., 2017). Pru-
dent use of antibiotics is therefore indicated and if
patients only show mild, transient clinical signs of
CIRDC, antimicrobial therapy will not generally
be required.
In summary, 100% protective immunity against
respiratory diseases is rare, and generally only a
reduction in clinical signs and excretion of pathogen
can be achieved through vaccination. Nevertheless,
vaccination against respiratory diseases is recommen-
ded where large numbers of animals come into close
proximity. Pets only exceptionally congregate in large
groups (e. g. in kennels, at dog shows, at puppy classes
or breeding facilities). Recommending vaccination
against pathogens of CIRDC in these cases, according
to the World Small Animal Veterinary Association
guidelines (Day et al., 2016), will directly provide
epidemiological advantages to the group and any
involved dog.
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CIRDC is an endemic worldwide syndrome
involving multiple viral as well as bacterial patho-
gens. It is observed in up to approximately 1% of in-
dividual dogs yearly, but can have a morbidity of
nearly 100% during outbreaks following stays at
places were many dogs congregate such as kennels,
dog shows and training classes. There are multiple
viral and bacterial causes of CIRDC, which can
all be primary pathogens, but often co-infect to
complicate the disease. Vaccines against four of the
causative pathogens are available that confer epide-
miological advantages by reducing the spread of the
pathogens, increasing herd immunity through shed-
ding of the vaccine and decreasing the need for anti-
biotic treatment. The prevalence of the agents
involved in CIRDC is changing as new pathogens
emerge and the importance of traditional pathogens
is shifting and continued surveillance is required
throughout Europe to track the evolution of the
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